Clinical trials: Overweight, Obesity
Overweight, Obesity
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide.
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- RENEW 2 (NCT07220759)
- Testing
- Cagrilintide
- Where
- 67 sites in United States, Argentina and 9 more
- Volunteers
- 330 people
- Sponsor
- Novo Nordisk A/S
Obese, Overweight
A Study of SA030 Injection in Overweight or Obese Participants
This study is the first time SA030 is being given to people. The goal is to understand how safe it is, how well it is tolerated, and how the body processes and responds to a single dose of SA030 in individuals who are overweight…
- Trial name
- NCT07479862
- Testing
- SA030 Injection
- Where
- 2 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Suzhou Siran Biotechnology Co.,Ltd.
Overweight and Obesity
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.
- Trial name
- NCT07313761
- Testing
- Maridebart Cafraglutide
- Where
- 4 sites in United States
- Volunteers
- 349 people
- Sponsor
- Amgen
Obesity
HERO Study: Helping Evaluate Reduction in Obesity
A prospective, international, multi-center study of clinical outcomes and estimated healthcare resource expenditures associated with the treatment of obesity using the LAP-BAND AP® Adjustable Gastric Banding System.
- Trial name
- NCT00953173
- Testing
- LAP-BAND AP® Adjustable Gastric Banding System
- Where
- 6 sites in United States, Australia and 4 more
- Volunteers
- 671 people
- Sponsor
- Apollo Endosurgery, Inc.
Hyperlipidemia
Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol
A Multicenter Randomized, Double-Blind, Placebo-Controlled Study to evaluate the efficacy, safety and tolerability of MBX-8025, a novel PPAR-d agonist to treat hyperlipidemia, insulin resistance and obesity in overweight…
- Trial name
- MBX-8025 (NCT00701883)
- Testing
- MBX-8025, Atorvastatin
- Where
- 28 sites in United States
- Volunteers
- 183 people
- Sponsor
- Gilead Sciences
Obesity
The USGI Medical ESSENTIAL Study for Weight Loss
This is a multicenter, randomized, evaluator and subject blinded, parallel-group, controlled study intended to evaluate the safety and efficacy of treating obese patients with the placement of g-Cath EZ suture anchors followed by…
- Trial name
- NCT01958385
- Testing
- placement of g-Cath EZ suture anchors, Diet and Exercise
- Where
- 11 sites in United States
- Volunteers
- 377 people
- Sponsor
- USGI Medical
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
- Trial name
- MARITIME-HF (NCT07037459)
- Testing
- Maridebart cafraglutide
- Where
- 686 sites in United States, Argentina and 33 more
- Volunteers
- 5,056 people
- Sponsor
- Amgen
Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese…
- Trial name
- NCT06628362
- Testing
- Enicepatide
- Where
- 70 sites in United States, Argentina and 4 more
- Volunteers
- 447 people
- Sponsor
- Carmot Therapeutics, Inc.
Muscle Loss, Obesity
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.
- Trial name
- QUALITY (NCT06282458)
- Testing
- Enobosarm, Semaglutide
- Where
- 14 sites in United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Veru Inc.
Obesity, Overweight
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year.
- Trial name
- NCT06683508
- Testing
- LY3549492
- Where
- 49 sites in United States
- Volunteers
- 288 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers, Obesity
Phase 1 Clinical Study of MWN117 Injection in Healthy Participants and Participants With Obesity
This study is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MWN117 injection in healthy and…
- Trial name
- NCT07824804
- Testing
- MWN117
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses
1. Study Objective i) To evaluate the safety, tolerability and pharmacokinetic/pharmacodynamic characteristics of HSG4112 after single and multiple oral administration of high doses in healthy subjects.
- Trial name
- NCT05310032
- Testing
- HSG4112
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Glaceum
Type 2 Diabetes, Obesity
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk.
- Conditions
- Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight
- Trial name
- ACHIEVE-4 (NCT05803421)
- Testing
- Orforglipron, Insulin Glargine
- Where
- 358 sites in United States, Argentina and 14 more
- Volunteers
- 2,749 people
- Sponsor
- Eli Lilly and Company
Sarcopenia, Body Composition
Validation of a Body-Composition Segmentation Software on a Diverse Public CT Scan Cohort
This study evaluates the standalone performance of Soma, a deep-learning software developed by Nucleo Research, Inc. for the automated segmentation of body-composition tissues (skeletal muscle, subcutaneous adipose tissue…
- Conditions
- Sarcopenia, Body Composition, Obesity
- Trial name
- SOMA (NCT07600866)
- Testing
- Soma Body-Composition Segmentation Software
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Nucleo Research, Inc.
Overweight, Obesity
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study
The purpose of this study is to determine whether the combination of two dietary supplements: MUSCLE 5, which contains protein, creatine and vitamin D and TRIM 7, which contains beet extract, caffeine, coenzyme Q10, alpha lipoic…
- Trial name
- NCT05384431
- Testing
- Muscle5 and TRIM7, Mixed exercise
- Where
- Canada
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Exerkine Corporation
Hyperphagia, Prader-Willi Syndrome
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101.
- Trial name
- HERO (NCT06828861)
- Testing
- ARD-101
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 68 people
- Sponsor
- Aardvark Therapeutics, Inc.
Obesity Type 2 Diabetes Mellitus, Type 2 Diabetes Mellitus
An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)
A worldwide study with extension in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug for weight loss on body weight.
- Trial name
- NCT00430742
- Testing
- Taranabant
- Volunteers
- 600 people
- Sponsor
- Merck Sharp & Dohme LLC
Overweight or Obese Participants Without Diabetes
A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes
To evaluate the efficacy of BGM0504 tablets compared with placebo in reducing body weight in overweight or obese participants without diabetes after 20 weeks of treatment.
- Trial name
- NCT07658560
- Testing
- BGM0504 tablets
- Where
- China
- Volunteers
- 200 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Metabolism and Nutrition Disorder, Obesity
Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects
This trial is conducted in the United States of America (USA). The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses of NNC9204-0530 alone…
- Trial name
- NCT02235961
- Testing
- NNC9204-0530, liraglutide
- Where
- United States
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions.
- Trial name
- NCT07792954
- Testing
- Berobenatide
- Where
- 34 sites in China
- Volunteers
- 300 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.